Regeneron Pharmaceuticals REGN Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's deferred tax assets and other non-current assets?
- Regeneron Pharmaceuticals (REGN) reported deferred tax assets and other non-current assets of $2.13B in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Regeneron Pharmaceuticals's deferred tax assets and other non-current assets increased by 52.9% year-over-year, from $1.39B to $2.13B.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 61.0% compound annual growth rate (CAGR), from $168.1M to $1.82B.